Jonathan Jay Mazelsky has demonstrated a clear selling bias in his recent insider transactions, particularly concentrated in shares of IDEXX Laboratories (IDXX). Between February 26 and February 27, 2026, Mazelsky executed 13 sales totaling approximately $12.8 million, with individual transactions ranging from $713,377 to $2.41 million. The largest single sale occurred on February 26, when he disposed of shares worth $2.41 million, followed closely by another sale of $1.88 million the same day. These disposals were partially offset by a single acquisition of $995,894 worth of IDXX shares on February 27, though this purchase represented just 7.7% of the total value sold during this period.
Mazelsky’s trading history shows activity in only two companies—IDXX and Dentsply Sirona (XRAY)—with the vast majority of transactions involving IDXX. His overall trading pattern reveals a significant imbalance, with total sales of $42.85 million dwarfing his total purchases of $6.61 million across 80 reported transactions. The XRAY transactions, all classified as acquisitions, were minimal in comparison, with the most recent involving less than $1,900 in value. The concentrated selling in IDXX shares in early 2026 suggests a shift in Mazelsky’s holdings, though whether this reflects portfolio rebalancing, liquidity needs, or other financial considerations cannot be determined from the filings alone.
AI-assisted summary